新闻中心
您的位置:首页>>新闻中心>>通知公告>>文章阅读
  站内搜索
WeNALT (WEHI, Nanjing Uni, LaTrobe Uni) 国际讲学系列
发布日期:2017-09-30    浏览次数:338次    关键词:

南京大学生命科学学院与澳大利亚墨尔本大学及沃尔特和伊丽莎·霍尔医学研究所(The Walter and Eliza Hall InstituteWEHI

和拉筹伯大学(LaTrobe)国际讲学系列

时间:2017109—14

地点: 南京大学生命科学学院A321A430会议室

Monday October 9th- DrMelissa Davis and Dr Ka Yee Fung

Lecture 1:Cancer: Introduction to the hallmark attributes of cancer

9.00AM-10.00AM    A321

This lecture will introduce the hallmarks of cancer, and discuss the role of these processesin promoting tumours and disease progression.

  • Introduction to the hallmarks of cancer

  • Hallmarks in the context of cancer cells

  • Hallmarks in the context of tumours and

Lecture 2: Details: The role of Inflammation and interactions with the Immune System

10.20AM-11.20AM    A321  

This lecturewill discuss the role of inflammation in promoting tumours, and explore theinteraction between the immune system and cancer.

Tuesday October 10th - Dr Melissa Davis and Dr Charity Law

Lecture 3: Cancer: Subtypes andmolecular phenotypes

9.00AM-10.00AM    A430  

This lecturewill introduce the various dimensions of heterogeneity in cancers, includingthe roles of signalling pathways, driver mutations, and regulation.

  • Cancer subtypes – molecular differences that characterise different types of disease

  • Genetics and driver mutations

  • Signalling pathways as drivers of disease and response to therapy

Lecture 4: Details: Measuring molecular phenotype of cancer

10.20AM-11.20AM    A430

This lecture will discuss approaches for measuring the molecular phenotype of cancers, and how these datasets can be analysed, with a specific focus on the transcriptome.

  • High-throughput measurements of molecular phenotype, including next generation RNA sequencing

  • Analysis of transcriptomic data

  • Exploring subtypes through differential expression and clustering

Wednesday October 11th - Dr Melissa Davis and Dr Ka Yee Fung

Lecture 5: Towards precisionmedicine

9.00AM-10.00AM    A321  

This lecturewill introduce the concept of precision medicine, and the progress we have madefrom traditional approaches to new techniques.

  • Historical approaches to diagnosis and therapy

  • Current and emerging approaches for diagnosis and the design of therapy

  • Precision treatment – targeting specific genes, or patient specific therapy?

Lecture 6: Details: Organoidculture

10.20AM-11.20AM    A321  

This lecturewill explore organoid culture as a technique in precision medicine.

Thursday October 12th- A.Prof Marc Kvansakul

Lecture 7: Introduction to Structural biology – how to see your molecules in action

2.00PM-3.00PM    A321

This lecture will introduce the three coremethods of structural biology, X-ray crystallography, NMR and cryo EM, and givean overview of the their working principals and applications

  • Fundamental working principles of major structural biology techniques

  • How to tackle a structural biology project – choice of method, strengths and limitations

  • Sample preparation – what does it take to prepare a high quality sample

Lecture 8: Details: Structure guided drug discovery for cancer therapy

3.20PM-4.20PM    A321  

This lecture will provide detailed examples ofthe use of structural biology to move from targets to therapies

  • Introduction to SAR by NMR and fragment based drug discovery

  • Introduction to apoptosis signalling in mammals

  • Venetoclax – how to design a blockbuster next generation drug for cancer therapy

Friday October 13th– Dr Andrew Webb

Lecture 9: Introduction to Proteomics– Mass Spectrometry basic to PTMs and Accurate Quantitation

9.00AM-10.00AM    A321    

This lecture will introduce the methods of Proteomicsin life science research and include:

  • Introduction to mass spectrometry

  • Experimental design (Types of labelling techniques, statistical considerations)

  • Sample preparation methods (“Do’s and Don’ts of MS”, dynamic range considerations)

  • Fundamentals of MS instrumentation (liquid chromatography, TOF vs Orbitrap)

Lecture 10: Proteomics applicationsand precision medicine

10.20AM-11.20AM    A321

  • Bioinformatic analysis and interpretation of MS data (database searching, peptide-based quantitation, heatmap analysis)

  • Applications of MS technology in biology (Intact or Top down MS, structural proteomics)

  • Application of MS technology in clinical applications

Saturday October 14th– Prof David Huang

Lecture 11: Current challengesand barriers to effective cancer therapy

9.00AM-10.00AM    A321    


Lecture 12: Howmight treatment for a cancer patient look like in 25 years’ time?

10.20AM-11.20AM    A321


Dr Melissa Davis
is a computational cancerbiologist, and Laboratory Head at the Walter and Eliza Hall Institute ofMedical Research. She us an expert in the analysis and reconstruction ofmolecular mechanisms of cancer progression and response to therapy. Herbackground is genetics and computational cell biology, and she currently holdsa National Breast Cancer Foundation Fellowship to study molecular mechanisms ofbreast cancer metastasis. Dr Davis and her team work on the analysis of large,heterogeneous datasets from national and international cancer projects and seekto discover patterns in the data that will help to target patient treatment andpersonalise cancer therapy.

Dr Charity Law is a statistical bioinformatician whose work focuses predominantly on gene expression analyses of high-throughput data. The impact of her work is best illustrated by the popularity of voom, a method for RNA-seq gene expression analysis that she developed which has been cited 750 times since its publication in 2014 (Source: Google Scholar). She currently holds the position of senior research officer in the Molecular Medicine Division at Walter and Eliza Hall Institute of Medical Research, Australia. In addition to differential gene expression, her research interests include differential isoform usage, transcript expression, and histone modification analyses.

Dr Ka Yee Fung completed her PhD studies at Monash University, under the mentorship of Prof Paul Hertzog and her postdoctoral studies at The University of Melbourne, under the mentorship of Prof Liz Hartland. Dr Fung is now a Senior Postdoctoral Fellow in the Inflammation Division at the Walter and Eliza Hall Institute of Medical Research. Her primary research interest involves investigation into how the inflammatory response contributes to cancer development and progression, and the Putoczki Lab, where she is based, is working towards understanding how cytokines modulates the immunological response in the tumour microenvironment, which could provide a new therapeutic target for inflammation-associated cancers.

A.Prof Marc Kvansakul After completing an undergraduate degree inBiochemistry at Imperial College London, Marc was awarded a Wellcome TrustPrize Studentship to pursue a PhD with Prof. Erhard Hohenester at ImperialCollege London, investigating collagen-binding proteins in the extracellularmatrix. In 2004 he took up a Leukemia & Lymphoma Society of Americafellowship to work with Prof. Peter Colman at the Walter and Eliza HallInstitute. In 2010, Marc was awarded an NHMRC Career Development Award toestablish the inaugural structural biology laboratory at La Trobe University.Now an ARC Future Fellow, his work has expanded into the role of innateimmunity molecules in anti-microbial defence.

Dr AndrewWebb is head of the recently formed WEHI ProteomicsResearch Laboratory. He has helped to establish the laboratory as an integralcollaborative resource with the specific aim of applying the next-generation ofproteomics to important biological questions relevant to human health. His ownresearch has focused on understanding the mechanisms of ubiquitin andposttranslational modifications during signal transduction. More recently, hehas established a broad computational proteomics program that incorporatesmachine learned classification into the analysis of proteomic datasets, and isusing quantitative proteomics to identify peptide signatures that distinguishdisease patients from all other control patient groups.

Professor David Huang is a laboratory head at the Walter and Eliza Hall Institute (WEHI) of Medical Research in Melbourne, Australia and Professor in the Department of Medical Biology, Melbourne University. He is a medical graduate and trained in Internal Medicine and in Hematology. He has led an independent research program since 2000. His research interests are studying the molecular mechanisms that regulate cell death in mammalian cells, understanding how deregulation of this process can lead to diseases such as cancer and how these can be targeted for improved therapies. His laboratory has made significant contributions to targeting the BCL2-regulated cell survival pathway for treating patients with cancers. One of these is venetoclax (ABT-199) that has been approved by the US FDA for treating patients with high-risk chronic lymphocytic leukemia (CLL). In 2016, the work of the team he led was awarded the 2016 Johnson & Johnson Eureka Prize for Innovation in Medical Research.



苏ICP备10085945-1号  南信备252号  南京大学生命科学学院版权所有  地址:南京市仙林大道163号南京大学仙林校区
南京锐美捷信息技术有限公司 技术支持  后台管理在线咨询